Phase 2Data readout

RP2 in comb w/ atezolizumab and bevacizumab

Hepatocellular carcinoma

REPLReplimune Group Inc

Expected catalystDecember 31, 2026Company guidance: Dec 31, 2026

Catalyst overview

Event details

Drug or asset: RP2 in comb w/ atezolizumab and bevacizumab
Development stage: Phase 2
Event type: Data readout
Indication: Hepatocellular carcinoma

Research summary

What is being tracked?

This catalyst tracks a Phase 2 data readout for RP2 in comb w/ atezolizumab and bevacizumab in Hepatocellular carcinoma. The expected timing is based on the latest available company guidance and may change.

Development notes

06/29/26:- PR No update. 08/14/26:- PR No update.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Source URL not provided

Phase 2Data readout

RP2 in comb w/ atezolizumab and bevacizumab

Hepatocellular carcinoma

REPLReplimune Group Inc

Expected catalystDecember 31, 2026Company guidance: Dec 31, 2026

Catalyst overview

Event details

Drug or asset: RP2 in comb w/ atezolizumab and bevacizumab
Development stage: Phase 2
Event type: Data readout
Indication: Hepatocellular carcinoma

Research summary

What is being tracked?

Development notes

06/29/26:- PR No update. 08/14/26:- PR No update.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Source URL not provided

RP2 in comb w/ atezolizumab and bevacizumab

Event details

What is being tracked?

Development notes

Primary source

Related pipeline programs

RP2 + Opdivo

RP2 in comb w/ atezolizumab and bevacizumab

Event details

What is being tracked?

Development notes

Primary source

Related pipeline programs

RP2 + Opdivo